Lindan R
Postgrad Med J. 1979;55 Suppl 4:67-9.
The clinical efficacy and safety of cefaclor, a new oral cephalosporin, was compared with that of amoxycillin in the treatment of lower urinary tract infections in 61 patients with chronic non-urinary tract disease. Thirty-six patients received cefaclor and 25 received amoxycillin doses of 250 mg every 8 hours for 7 to 10 days. The therapeutic effectiveness of cefaclor was significantly better than that of amoxycillin, and it appeared to be well tolerated and free of adverse side effects. It produced no allergic reactions in 4 patients with a history of penicillin allergy and was effective against Klebsiella strains resistant to the ampicillins. There was no evidence of any haematological, renal or hepatic toxicity from either drug at the dosage used.
将一种新型口服头孢菌素头孢克洛与阿莫西林的临床疗效及安全性进行了比较，以治疗61例患有慢性非泌尿系统疾病的下尿路感染患者。36例患者接受头孢克洛治疗，25例患者接受阿莫西林治疗，均每8小时服用250毫克，持续7至10天。头孢克洛的治疗效果明显优于阿莫西林，且似乎耐受性良好，无不良副作用。在4例有青霉素过敏史的患者中未产生过敏反应，并且对耐氨苄青霉素的克雷伯菌菌株有效。在所使用的剂量下，两种药物均未显示出任何血液学、肾脏或肝脏毒性的证据。
